{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:30:31Z","timestamp":1792103431784,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020953","name":"Taiwan Centers for Disease Control","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jmii.2025.07.013","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:16:13Z","timestamp":1753888573000},"page":"735-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Active drug-safety monitoring and management in the treatment of rifampicin-resistant tuberculosis: a nationwide multicenter prospective study"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-8414","authenticated-orcid":false,"given":"Chou-Jui","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Bin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Tien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Jyh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-2490","authenticated-orcid":false,"given":"Chen-Yuan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2025.07.013_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2025.07.013_bib2","year":"2019"},{"key":"10.1016\/j.jmii.2025.07.013_bib3","series-title":"Global Tuberculosis Report 2024","first-page":"50","year":"2024"},{"key":"10.1016\/j.jmii.2025.07.013_bib4","series-title":"Framework for Implementation","article-title":"Active tuberculosis drug-safety monitoring and management (aDSM)","year":"2015"},{"key":"10.1016\/j.jmii.2025.07.013_bib5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1183\/09031936.06.00125705","article-title":"Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study","volume":"28","author":"Chiang","year":"2006","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jmii.2025.07.013_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciy066","article-title":"Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up","volume":"67","author":"Yu","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jmii.2025.07.013_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214792","article-title":"Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2025.07.013_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jmii.2024.04.008","article-title":"Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: the role of new and repurposed drugs","volume":"57","author":"Huang","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2025.07.013_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculois (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2025.07.013_bib10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.07.013_bib11","series-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis. 2016 Update","year":"2016"},{"key":"10.1016\/j.jmii.2025.07.013_bib12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jmii.2024.08.002","article-title":"Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: findings of aDSM in Taiwan","volume":"57","author":"Lin","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"10.1016\/j.jmii.2025.07.013_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","article-title":"Harmonisation in Pharmacovigilance","volume":"10","author":"Edwards","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.jmii.2025.07.013_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2025.07.013_bib16","article-title":"WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment","year":"2022","journal-title":"Web Annexes"},{"key":"10.1016\/j.jmii.2025.07.013_bib17","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","article-title":"Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","author":"Wu","year":"2016","journal-title":"Am J Therapeut"},{"issue":"153","key":"10.1016\/j.jmii.2025.07.013_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0115-2018","article-title":"Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences","volume":"28","author":"Tiemersma","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jmii.2025.07.013_bib19","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.07.013_bib20","series-title":"International Union against Tuberculosis and Lung Disease","first-page":"1","article-title":"Interventions for tuberculosis control and elimination","author":"Rieder","year":"2002"},{"key":"10.1016\/j.jmii.2025.07.013_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciy066","article-title":"Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up","volume":"67","author":"Yu","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:12:11Z","timestamp":1772892731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225001483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1684118225001483"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.07.013","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active drug-safety monitoring and management in the treatment of rifampicin-resistant tuberculosis: a nationwide multicenter prospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}